- Quantum Leap Healthcare Collaborative and Ambrx Biopharma Inc AMAM have announced the selection of Ambrx's antibody-drug conjugate (ADC) ARX788 for a new investigational treatment arm in the I-SPY 2.2 TRIAL.
- Sponsored by Quantum Leap, I-SPY 2.2 is an adaptive Phase 2 trial that evaluates emerging targeted agents, allowing those agents to either be combined with less toxic chemotherapeutic regimens or replace cytotoxic chemotherapy entirely.
- ARX788 will be evaluated as a monotherapy, combined with the PD-1 targeting checkpoint inhibitor cemiplimab, in HER2-positive early-stage breast cancer in the neoadjuvant setting.
- Ambrx anticipates the ARX788 arms to begin enrolling patients in May 2022.
- Price Action: AMAM shares are up 10.90% at $4.08 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
